Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science for health event in September the visionary Christian Homsy, former Celyad CEO, will be presenting one of the keynote talks. In this BioVox interview, we asked him to share his thoughts on the challenges faced by a company that’s pushing boundaries in the oncology space.
Food waste is a major global issue exacerbated by premature fruit spoilage. A US company, StixFresh, is working together with VIB-KU Leuven Prof Patrick Van Dijck to develop a solution to the problem. The company has created stickers coated in a plant-based antimicrobial formula that protects fruit from fungal infections, extending their shelf life by several weeks.
WELBIO has received a truly unique form of acknowledgement: a newly discovered bacterium has been named after the research institute. The human gut microbe was discovered during a project led by Prof. Patrice Cani (WELBIO-UCLouvain), who proposed the name Dysosmobacter welbionis.
Belgian researchers have developed edible antibodies that can prevent gut bacterial infections. Normally antibodies need to be injected, but the antibodies developed by Dr. Vikram Virdi in the group of Dr. Nico Callewaert can instead be mixed with food and eaten. These antibodies are produced using yeast and have so far been shown to protect piglets from diarrhea-causing enterotoxigenic E. coli, which is a serious issue in pig farming. The edible antibody concept also has enormous potential for applications in human medicine, such as in preventing diarrheal disease outbreaks following natural disasters.
A microchip engineer might seem like an odd fit for a keynote speaker at an event focused on cell therapy, but at Science for health Peter Peumans will be presenting one of the day’s visionary talks. Peumans will draw on his experience with the tech powerhouse imec to give us an insider’s perspective on the role new chip technologies may soon take on in the cell therapy field.
Science for health is Belgium’s new research event, set to promote more collaborations in our stellar life sciences ecosystem. The September event will bring together experts from across the board; academics, industry leaders, clinicians and service providers; facilitating the formation of new research connections. The ultimate aim is not only to showcase Belgian research, but to create value for patients by encouraging new and innovative partnerships. For the inaugural 2019 edition, the focus is on the exciting field of cell therapy.
Just days before KBC Securities’ "State of the Union" announcement on how well Belgian biotech has been faring in 2019, Confo Therapeutics closed a terrific series A financing round. The company raised 30 million euros, which will be used to accelerate their drug discovery activities using their camelid-based ConfoBody™ technology.
This month marked the crystal anniversary of the life sciences networking event Knowledge for Growth. The event was a huge success, with 1300+ attendees representing 600+ companies from 20+ countries around the world. The theme for this year was “Precision in Life Sciences”, with the fascinating plenary talks discussing the effect of digitalization on healthcare.
Belgium has once again strengthened its position as Europe's biotech leader. Today, Belgian biotech companies comprise 23 percent of the total market value of all public European biotech companies. Compared to the end of April 2018, the value of Belgian biotech companies increased by 12.5 percent from 24 to 27 billion euros. A few Belgian biotech giants such as Galapagos, argenx and UCB, are responsible for this growth. This according to figures announced by KBC Securities during the "State of the Union" event of the Flemish biotech sector federation flanders.bio and VIB on the eve of the large "knowledge for growth" congress in Ghent.
Have you ever considered how scientists are able to count transparent cells in a see-through solution? Traditional methods involve dyes, microscopes, time and effort. Now there’s a new technology on the market: Ovizio Imaging Systems has developed a technical solution to this longstanding problem. Using an imaging technique called digital holographic microscopy, Ovizio’s devices perform cell counts by reconstructing 3D images using light. This new type of imaging provides quantitative information about cells, including their number, morphology and viability, all without a drop of dye!
Due to climate change, two species of tropical mosquitoes are spreading into Europe at increasing rates. Their presence is linked to a range of tropical viruses, including dengue, yellow fever, chikungunya and Zika. With an increase in disease-ridden insects, we’re likely to start seeing these infections at higher rates in European countries, in Belgium and beyond.
Bioscience engineers at KU Leuven have created a record-breaking hydrogen gas panel. The panel is capable of producing 250 liters of hydrogen gas per day; enough that just 20 panels could provide a family’s electricity and heating needs for a whole European winter. The Belgian device is an innovative step forward for clean energy and sustainability around the globe.